RT Kakade, SD Firke, PS Bafna, AK Tilva.
R.T. Kakade1, S.D.Firke2, P.S. Bafna2, A.K. Tilva1
1NGSPMs College of Pharmacy, Anjaneri, Nashik, Maharashtra.
2H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra
Volume - 4,
Issue - 3,
Year - 2012
Acquired immunodeficiency syndrome (AIDS) causes an irreversible destruction of immune system. Currently, used drugs for treatment of HIV/AIDS act through inhibition of important viral enzymes such as reverse transcriptase, protease and/or integrase. Uncoating inhibitor has also been approved for treatment of AIDS with novel mode of action. However, it is now evident that the existing armoury of antiretroviral and even their triplet (cocktail) and/or quadruple (highly active antiretroviral therapy, HAART), will not lead to eradication of HIV infection. Therefore recently scientists have proposed different targets and treatment approaches towards the HIV/AIDS, which include entry inhibitors, transcription inhibitors, uncoating inhibitors, zinc finger inhibitors, gene therapy.
Cite this article:
RT Kakade, SD Firke, PS Bafna, AK Tilva. Overview on Acquired immunodeficiency syndrome . Research J. Pharmacology and Pharmacodynamics. 4(3): 2012;158-162.
RT Kakade, SD Firke, PS Bafna, AK Tilva. Overview on Acquired immunodeficiency syndrome . Research J. Pharmacology and Pharmacodynamics. 4(3): 2012;158-162. Available on: https://rjppd.org/AbstractView.aspx?PID=2012-4-3-16